Breaks Categories: News

TuesdayMay 31, 2022 12:52 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Files IND Application for Phase-2 Trial of FSD-PEA

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Health Canada. The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder. “Our current submissions of applications to FDA and Health Canada for FSD-201 efficacy trials represent a significant milestone in our drug development efforts,” said Zeeshan Saeed, co-founder and president of FSD Pharma. “With our elite…

Continue Reading

TuesdayMay 31, 2022 11:15 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly. Based on preclinical studies, our proprietary psilocybin analog…

Continue Reading

WednesdayMay 25, 2022 2:07 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive experience in raising capital and corporate strategy, and his expertise is well-suited to support the company’s focus on advancing the delivery of psychedelic medicines. Currently managing director at 21 Corporate, an Australia-based corporate advisory firm, Ntoumenopoulos is also a strategic investment adviser at Freeman Road, an investment group specializing in health and early-stage medtech companies. Ntoumenopoulos is also a director at Race Oncology and ResApp…

Continue Reading

TuesdayMay 24, 2022 1:11 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Issuance of Circular, Incentive Plan and Granting of PSUs

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022. The circular is available on the company’s profile on SEDAR at www.SEDAR.com. In addition, to provide added flexibility to its executive compensation program, FSD Pharma on May 16, 2022, adopted an equity incentive plan (the “EIP”) pursuant to which it may grant shares, restricted share units, performance share units (“PSUs”) and…

Continue Reading

ThursdayMay 19, 2022 11:37 am

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made in this study, which seeks to examine the effects of psilocybin as an anti-inflammatory…

Continue Reading

WednesdayMay 18, 2022 12:31 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving industries. During the interview, hosted by Stuart Smith, Weisblum talks about his own background and experience in the industry as well as Silo Pharma’s business model and the company’s recent milestones. Weisman has been building and managing businesses for more than two decades and has…

Continue Reading

WednesdayMay 18, 2022 12:15 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Share Expansion Strategy at H.C. Wainwright Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding participation of its CEO Matt Stang at the H.C. Wainwright Annual Global Life Sciences Conference taking place May 23-26, 2022, in Miami, Florida. The four-day event will feature keynote presentations, investor one-on-one meetings, networking opportunities and evening entertainment. At this year's conference, Stang will present the company's expansion strategy and participate in one-on-one meetings. Interested parties should visit https://ibn.fm/UGjjp to register for the event. To view the full press release, visit https://ibn.fm/EkzBY About Delic Holdings Corp. Delic…

Continue Reading

TuesdayMay 17, 2022 2:01 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments…

Continue Reading

MondayMay 16, 2022 2:37 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Issues Update on Default Status

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that it is providing a default status report; the report is being released in accordance with the alternative information guidelines set out in National Policy 12-203 — Management Cease Trade Orders (“NP 12-203”). According to the announcement, Delic is experiencing delays to its audit, which means that the required annual financial statements and management's discussion and analysis for FY 2021 have been delayed as well. The company had requested that a management cease trade order (“MCTO”) be imposed as a result…

Continue Reading

ThursdayMay 12, 2022 12:29 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Enters New VA Partnership in Arizona

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today announced a new partnership with the Veterans Administration (“VA”) in Arizona. Per the update, veterans suffering from treatment-resistant depression, PTSD and anxiety will have access to ketamine therapy at KWC Arizona clinics located in Phoenix, Tucson and Mesa - Gilbert at no out-of-pocket cost with prior authorization from the VA. This new VA partnership is in addition to the one established with the Burnsville, Minnesota-based KWC. “At KWC, we take great pride in supporting our…

Continue Reading